GlassScriptPhysician profile
Samuel Ryan Faught
NPI 1659469476
$2,440.64
in general payments reported to CMS, 2019-2025
36 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.15 · 2021: $70.85 · 2022: $763 · 2023: $817 · 2024: $466 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $271.39 | 2022-2025 | |
| Pfizer INC. | $170.22 | 2023-2025 | |
| Seagen INC. | $157.95 | 2022-2023 | Tukysa, Adcetris |
| Merck Sharp & Dohme LLC | $156.87 | 2021-2025 | Keytruda, Lynparza |
| Blue Earth Diagnostics | $142.63 | 2021-2025 | Posluma |
| Astrazeneca Pharmaceuticals LP | $137.48 | 2022-2025 | Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $109.08 | 2019-2025 | Rybrevant |
| Accuray Incorporated | $106.23 | 2022 | |
| Aveo Pharmaceuticals, INC. | $96.38 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $93.07 | 2022-2023 | Libtayo |
| Daiichi Sankyo INC. | $80.61 | 2022-2023 | Enhertu |
| Novocure INC. | $72.60 | 2019-2023 | Optune |
| Eisai INC. | $70.87 | 2022-2023 | |
| Adc Therapeutics America, INC. | $64.52 | 2022-2023 | |
| Servier Pharmaceuticals LLC | $64.12 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $61.03 | 2019-2025 | Spaceoar System |
| Stemline Therapeutics INC. | $51.65 | 2023 | Orserdu |
| Sumitomo Pharma America, INC. | $49.96 | 2023-2024 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $49.24 | 2022-2024 | |
| Genzyme Corporation | $48.84 | 2022 | |
| Lilly USA, LLC | $42.89 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Mirati Therapeutics, INC. | $37.58 | 2023 | Krazati |
| Incyte Corporation | $36.64 | 2022-2023 | Jakafi |
| Coherus Oncology, INC. | $31.38 | 2022-2023 | |
| Tactile Systems Technology INC | $31.00 | 2022 | |
| Puma Biotechnology, INC. | $29.57 | 2023-2024 | |
| Amgen INC. | $26.85 | 2023 | Lumakras, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $23.05 | 2023 | Fruzaqla |
| Cumberland Pharmaceuticals, INC. | $17.87 | 2024 | Sancuso |
| Tersera Therapeutics LLC | $17.12 | 2022 | |
| Kyowa Kirin, INC. | $17.09 | 2022 | |
| G1 Therapeutics, INC. | $17.01 | 2022 | |
| Siemens Medical Solutions USA, INC. | $16.09 | 2023 | Truebeam |
| Teleflex LLC | $14.99 | 2024 | |
| Myovant Sciences INC. | $13.92 | 2022 | |
| Genentech USA, INC. | $12.85 | 2023 | Lunsumio, Columvi, Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Faught listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.